Cargando…

Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer

BRCA 1/2 genes mutation status can already determine the therapeutic algorithm of high grade serous ovarian cancer patients. Nevertheless, its assessment is not sufficient to identify all patients with genomic instability, since BRCA 1/2 mutations are only the most well-known mechanisms of homologou...

Descripción completa

Detalles Bibliográficos
Autores principales: Nero, Camilla, Boldrini, Luca, Lenkowicz, Jacopo, Giudice, Maria Teresa, Piermattei, Alessia, Inzani, Frediano, Pasciuto, Tina, Minucci, Angelo, Fagotti, Anna, Zannoni, Gianfranco, Valentini, Vincenzo, Scambia, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570450/
https://www.ncbi.nlm.nih.gov/pubmed/36232628
http://dx.doi.org/10.3390/ijms231911326
_version_ 1784810109727145984
author Nero, Camilla
Boldrini, Luca
Lenkowicz, Jacopo
Giudice, Maria Teresa
Piermattei, Alessia
Inzani, Frediano
Pasciuto, Tina
Minucci, Angelo
Fagotti, Anna
Zannoni, Gianfranco
Valentini, Vincenzo
Scambia, Giovanni
author_facet Nero, Camilla
Boldrini, Luca
Lenkowicz, Jacopo
Giudice, Maria Teresa
Piermattei, Alessia
Inzani, Frediano
Pasciuto, Tina
Minucci, Angelo
Fagotti, Anna
Zannoni, Gianfranco
Valentini, Vincenzo
Scambia, Giovanni
author_sort Nero, Camilla
collection PubMed
description BRCA 1/2 genes mutation status can already determine the therapeutic algorithm of high grade serous ovarian cancer patients. Nevertheless, its assessment is not sufficient to identify all patients with genomic instability, since BRCA 1/2 mutations are only the most well-known mechanisms of homologous recombination deficiency (HR-d) pathway, and patients displaying HR-d behave similarly to BRCA mutated patients. HRd assessment can be challenging and is progressively overcoming BRCA testing not only for prognostic information but more importantly for drugs prescriptions. However, HR testing is not already integrated in clinical practice, it is quite expensive and it is not refundable in many countries. Selecting patients who are more likely to benefit from this assessment (BRCA 1/2 WT patients) at an early stage of the diagnostic process, would allow an optimization of genomic profiling resources. In this study, we sought to explore whether somatic BRCA1/2 genes status can be predicted using computational pathology from standard hematoxylin and eosin histology. In detail, we adopted a publicly available, deep-learning-based weakly supervised method that uses attention-based learning to automatically identify sub regions of high diagnostic value to accurately classify the whole slide (CLAM). The same model was also tested for progression free survival (PFS) prediction. The model was tested on a cohort of 664 (training set: n = 464, testing set: n = 132) ovarian cancer patients, of whom 233 (35.1%) had a somatic BRCA 1/2 mutation. An area under the curve of 0.7 and 0.55 was achieved in the training and testing set respectively. The model was then further refined by manually identifying areas of interest in half of the cases. 198 images were used for training (126/72) and 87 images for validation (55/32). The model reached a zero classification error on the training set, but the performance was 0.59 in terms of validation ROC AUC, with a 0.57 validation accuracy. Finally, when applied to predict PFS, the model achieved an AUC of 0.71, with a negative predictive value of 0.69, and a positive predictive value of 0.75. Based on these analyses, we have planned further steps of development such as proving a reference classification performance, exploring the hyperparameters space for training optimization, eventually tweaking the learning algorithms and the neural networks architecture for better suiting this specific task. These actions may allow the model to improve performances for all the considered outcomes.
format Online
Article
Text
id pubmed-9570450
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95704502022-10-17 Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer Nero, Camilla Boldrini, Luca Lenkowicz, Jacopo Giudice, Maria Teresa Piermattei, Alessia Inzani, Frediano Pasciuto, Tina Minucci, Angelo Fagotti, Anna Zannoni, Gianfranco Valentini, Vincenzo Scambia, Giovanni Int J Mol Sci Article BRCA 1/2 genes mutation status can already determine the therapeutic algorithm of high grade serous ovarian cancer patients. Nevertheless, its assessment is not sufficient to identify all patients with genomic instability, since BRCA 1/2 mutations are only the most well-known mechanisms of homologous recombination deficiency (HR-d) pathway, and patients displaying HR-d behave similarly to BRCA mutated patients. HRd assessment can be challenging and is progressively overcoming BRCA testing not only for prognostic information but more importantly for drugs prescriptions. However, HR testing is not already integrated in clinical practice, it is quite expensive and it is not refundable in many countries. Selecting patients who are more likely to benefit from this assessment (BRCA 1/2 WT patients) at an early stage of the diagnostic process, would allow an optimization of genomic profiling resources. In this study, we sought to explore whether somatic BRCA1/2 genes status can be predicted using computational pathology from standard hematoxylin and eosin histology. In detail, we adopted a publicly available, deep-learning-based weakly supervised method that uses attention-based learning to automatically identify sub regions of high diagnostic value to accurately classify the whole slide (CLAM). The same model was also tested for progression free survival (PFS) prediction. The model was tested on a cohort of 664 (training set: n = 464, testing set: n = 132) ovarian cancer patients, of whom 233 (35.1%) had a somatic BRCA 1/2 mutation. An area under the curve of 0.7 and 0.55 was achieved in the training and testing set respectively. The model was then further refined by manually identifying areas of interest in half of the cases. 198 images were used for training (126/72) and 87 images for validation (55/32). The model reached a zero classification error on the training set, but the performance was 0.59 in terms of validation ROC AUC, with a 0.57 validation accuracy. Finally, when applied to predict PFS, the model achieved an AUC of 0.71, with a negative predictive value of 0.69, and a positive predictive value of 0.75. Based on these analyses, we have planned further steps of development such as proving a reference classification performance, exploring the hyperparameters space for training optimization, eventually tweaking the learning algorithms and the neural networks architecture for better suiting this specific task. These actions may allow the model to improve performances for all the considered outcomes. MDPI 2022-09-26 /pmc/articles/PMC9570450/ /pubmed/36232628 http://dx.doi.org/10.3390/ijms231911326 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nero, Camilla
Boldrini, Luca
Lenkowicz, Jacopo
Giudice, Maria Teresa
Piermattei, Alessia
Inzani, Frediano
Pasciuto, Tina
Minucci, Angelo
Fagotti, Anna
Zannoni, Gianfranco
Valentini, Vincenzo
Scambia, Giovanni
Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer
title Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer
title_full Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer
title_fullStr Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer
title_full_unstemmed Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer
title_short Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer
title_sort deep-learning to predict brca mutation and survival from digital h&e slides of epithelial ovarian cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570450/
https://www.ncbi.nlm.nih.gov/pubmed/36232628
http://dx.doi.org/10.3390/ijms231911326
work_keys_str_mv AT nerocamilla deeplearningtopredictbrcamutationandsurvivalfromdigitalheslidesofepithelialovariancancer
AT boldriniluca deeplearningtopredictbrcamutationandsurvivalfromdigitalheslidesofepithelialovariancancer
AT lenkowiczjacopo deeplearningtopredictbrcamutationandsurvivalfromdigitalheslidesofepithelialovariancancer
AT giudicemariateresa deeplearningtopredictbrcamutationandsurvivalfromdigitalheslidesofepithelialovariancancer
AT piermatteialessia deeplearningtopredictbrcamutationandsurvivalfromdigitalheslidesofepithelialovariancancer
AT inzanifrediano deeplearningtopredictbrcamutationandsurvivalfromdigitalheslidesofepithelialovariancancer
AT pasciutotina deeplearningtopredictbrcamutationandsurvivalfromdigitalheslidesofepithelialovariancancer
AT minucciangelo deeplearningtopredictbrcamutationandsurvivalfromdigitalheslidesofepithelialovariancancer
AT fagottianna deeplearningtopredictbrcamutationandsurvivalfromdigitalheslidesofepithelialovariancancer
AT zannonigianfranco deeplearningtopredictbrcamutationandsurvivalfromdigitalheslidesofepithelialovariancancer
AT valentinivincenzo deeplearningtopredictbrcamutationandsurvivalfromdigitalheslidesofepithelialovariancancer
AT scambiagiovanni deeplearningtopredictbrcamutationandsurvivalfromdigitalheslidesofepithelialovariancancer